Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fasciitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Fasciitis. Displaying page 1 of 1.
    EudraCT Number: 2013-003556-20 Sponsor Protocol Number: RH4131-03 Start Date*: 2014-02-19
    Sponsor Name:Dept. of Intensive Care 4131, Copenhagen University Hospital, Rigshospitalet
    Full Title: Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
    Medical condition: Necrotizing Soft Tissue Infections
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10055648 Necrotizing fasciitis fungal LLT
    16.1 10021881 - Infections and infestations 10052892 Necrotising fasciitis fungal PT
    16.1 10021881 - Infections and infestations 10055647 Necrotizing fasciitis LLT
    16.1 10021881 - Infections and infestations 10055649 Necrotizing fasciitis staphylococcal LLT
    16.1 10021881 - Infections and infestations 10017068 Fournier's gangrene LLT
    16.1 10021881 - Infections and infestations 10028885 Necrotising fasciitis PT
    16.1 10021881 - Infections and infestations 10016229 Fasciitis necrotising LLT
    16.1 10021881 - Infections and infestations 10028886 Necrotising fasciitis NOS LLT
    16.1 10021881 - Infections and infestations 10028888 Necrotising fasciitis streptococcal PT
    16.1 10021881 - Infections and infestations 10028887 Necrotising fasciitis staphylococcal PT
    16.1 10021881 - Infections and infestations 10055650 Necrotizing fasciitis streptococcal LLT
    16.1 10021881 - Infections and infestations 10055643 Fasciitis necrotizing LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000575-32 Sponsor Protocol Number: 1 Start Date*: 2018-12-18
    Sponsor Name:Isabel Maria Ruiz
    Full Title: Results of the injection of botulinum toxin vs platelet rich plasma for the treatment of plantar fasciitis
    Medical condition: Plantar fasciitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10035155 Plantar fasciitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003123-37 Sponsor Protocol Number: Start Date*: 2006-10-12
    Sponsor Name:University Hospital Sint Radboud
    Full Title: Treatment with high dose Methotrexate in patients with eosinophilic fasciitis
    Medical condition: Eosinophilic fasciitis (EF) is a skin disorder involving the deep fascia, resulting in pain and swelling of extremities, cutaneous induration and joint contractures. Most patients require therapy. ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001125-15 Sponsor Protocol Number: ATB-202 Start Date*: 2018-07-16
    Sponsor Name:Atox Bio
    Full Title: Phase III, randomized, double-blind, placebo controlled, parallel-group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections (NSTI)
    Medical condition: Necrosis of soft tissue infections (NSTI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10065769 Soft tissue necrosis PT
    20.0 10021881 - Infections and infestations 10017068 Fournier's gangrene LLT
    20.1 10021881 - Infections and infestations 10028885 Necrotising fasciitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002929-36 Sponsor Protocol Number: TBFP2018 Start Date*: 2019-04-30
    Sponsor Name:Dra. Virginia Raquel Céspedes Nava
    Full Title: COMPARATIVE STUDY OF THE EFFICACY OF THE TREATMENT OF PLANTAR FASCITIS WITH INFILTRATION OF CORTICOIDS VS BOTULINIC TOXIN. ECOGRAPHIC FINDINGS
    Medical condition: Plantar fasciitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001257-18 Sponsor Protocol Number: 16400076 Start Date*: 2008-07-14
    Sponsor Name:Biomet Nederland BV
    Full Title: Use of PRP to treat plantar fasciitis, blinded and randomized as a multi center study
    Medical condition: Patients with plantar fasciitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005402-65 Sponsor Protocol Number: IIBSP-ANA-2013-163 Start Date*: 2015-01-19
    Sponsor Name:Institut de Recerca HSCSP
    Full Title: Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroids
    Medical condition: Inflammation in periarticular structures in patients refractory to NSAIDs and / or corticosteroids.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004354-15 Sponsor Protocol Number: DANPAPP Start Date*: 2017-12-13
    Sponsor Name: Rigshospitalet
    Full Title: Prevalence, pattern and disease course of arthritis and enthesitis in patients with psoriasis, and the effect of apremilast in subclinical US-defined psoriatic arthritis - A population-based study ...
    Medical condition: Psoriasis and psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000934-31 Sponsor Protocol Number: INN-TOP-005 Start Date*: 2015-07-10
    Sponsor Name:Innocoll Pharmaceuticals Limited
    Full Title: A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Pa...
    Medical condition: Diabetic Patients with an Infected Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10021784 Infected skin ulcer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) AT (Completed) BE (Completed) ES (Completed) SK (Completed) NL (Completed) GB (Completed) PL (Completed) HU (Completed) DK (Completed) LV (Completed) LT (Completed) EE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001771-21 Sponsor Protocol Number: XL184–311 Start Date*: Information not available in EudraCT
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-...
    Medical condition: Radioiodine-Refractory Differentiated Thyroid Cancer which has progressed after prior VEGFR-targeted therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) AT (Prematurely Ended) HU (Completed) ES (Ongoing) PL (Trial now transitioned) CZ (Completed) HR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023783-41 Sponsor Protocol Number: E7080-G000-303 Start Date*: 2011-07-05
    Sponsor Name:Eisai Limited
    Full Title: A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I- Refractory Differentiated Thyroid Cancer
    Medical condition: 131I-refractory differentiated thyroid cancer (DTC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) DE (Completed) ES (Completed) PL (Completed) DK (Completed) AT (Completed) IT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000102-33 Sponsor Protocol Number: 69HCL16_0079 Start Date*: 2018-03-22
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in children: a multicenter European randomized controlled trial
    Medical condition: toxic shock syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10044248 Toxic shock syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2007-004401-10 Sponsor Protocol Number: HYPRESS Start Date*: 2008-01-15
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Hydrocortisone for Prevention of Septic Shock Placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of low dose hydrocortisone to prevent the development of se...
    Medical condition: Patients with severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005534-38 Sponsor Protocol Number: E7080-G000-207 Start Date*: 2014-10-21
    Sponsor Name:Eisai Ltd.
    Full Title: Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma
    Medical condition: Refractory or relapsed solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) FR (Ongoing) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005199-27 Sponsor Protocol Number: E7080-G000-211 Start Date*: Information not available in EudraCT
    Sponsor Name:Eisai Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily W...
    Medical condition: 131I-refractory differentiated thyroid cancer (DTC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005933-12 Sponsor Protocol Number: E7080-G000-201 Start Date*: 2009-10-29
    Sponsor Name:Eisai Limited
    Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified...
    Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002419-48 Sponsor Protocol Number: GETNE-T2216 Start Date*: 2023-03-27
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
    Full Title: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
    Medical condition: Patients with radioiodine-refractory differentiated thyroid cancer (DTC).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003037-11 Sponsor Protocol Number: 21839 Start Date*: 2022-04-13
    Sponsor Name:Bayer AG
    Full Title: A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants wi...
    Medical condition: Chronic kidney disease in type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 29 22:11:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA